Loading...

Solanbridge Group, Inc.

SLNXPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.00
$0.00(0.00%)
U.S. Market opens in 9h 47m

Solanbridge Group, Inc. Fundamental Analysis

Solanbridge Group, Inc. (SLNX) shows weak financial fundamentals with a PE ratio of -7.14, profit margin of 0.00%, and ROE of 1.18%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.07

Areas of Concern

ROE1.18%
Operating Margin0.00%
Current Ratio0.04
We analyze SLNX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 52.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C
52.3/100

We analyze SLNX's fundamental strength across five key dimensions:

Efficiency Score

Weak

SLNX struggles to generate sufficient returns from assets.

ROA > 10%
-18.51%

Valuation Score

Excellent

SLNX trades at attractive valuation levels.

PE < 25
-7.14
PEG Ratio < 2
-0.07

Growth Score

Weak

SLNX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

SLNX shows balanced financial health with some risks.

Debt/Equity < 1
-0.16
Current Ratio > 1
0.04

Profitability Score

Weak

SLNX struggles to sustain strong margins.

ROE > 15%
118.24%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is SLNX Expensive or Cheap?

P/E Ratio

SLNX trades at -7.14 times earnings. This suggests potential undervaluation.

-7.14

PEG Ratio

When adjusting for growth, SLNX's PEG of -0.07 indicates potential undervaluation.

-0.07

Price to Book

The market values Solanbridge Group, Inc. at -5.31 times its book value. This may indicate undervaluation.

-5.31

EV/EBITDA

Enterprise value stands at -7.03 times EBITDA. This is generally considered low.

-7.03

How Well Does SLNX Make Money?

Net Profit Margin

For every $100 in sales, Solanbridge Group, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $1.18 in profit for every $100 of shareholder equity.

1.18%

ROA

Solanbridge Group, Inc. generates $-18.51 in profit for every $100 in assets, demonstrating efficient asset deployment.

-18.51%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

SLNX converts -0.00% of its market value into free cash.

-0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.14

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.07

vs 25 benchmark

P/B Ratio

Price to book value ratio

-5.31

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.16

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.04

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.18

vs 25 benchmark

ROA

Return on assets percentage

-18.51

vs 25 benchmark

ROCE

Return on capital employed

0.66

vs 25 benchmark

How SLNX Stacks Against Its Sector Peers

MetricSLNX ValueSector AveragePerformance
P/E Ratio-7.1429.43 Better (Cheaper)
ROE118.24%684.00% Weak
Net Margin0.00%-45067.00% (disorted) Weak
Debt/Equity-0.160.43 Strong (Low Leverage)
Current Ratio0.044.07 Weak Liquidity
ROA-1851.09%-17158.00% (disorted) Weak

SLNX outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Solanbridge Group, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ